FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
4D Molecular Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$12.29+0.15 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $863.64M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.45 (+24.90%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
4D Molecular Therapeutics, Inc. grew revenue 278712.1% to $92.01M over the twelve months to Jun 30, 2026. Free cash flow was -$109.62M.
Revenue
$92.01M
+278712.1% vs. a year earlier
Operating income
-$197.12M
TTM Q2 2026
Free cash flow
-$109.62M
FY2025
EPS, diluted
-$2.76
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $863.64M
- P/E ratio
- –
- Price to sales
- 9.39
- Price to book
- 2.12
- Dividend yield
- –
- Free cash flow yield
- -12.69%
Fundamentals
- Revenue
- $92.01M
- Net income
- -$179.18M
- EPS, diluted
- -$2.76
- Free cash flow
- -$109.62M
- Book value per share
- $5.80
- Diluted shares
- 70M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$92.01M+278712.1% YoY
Operating income
-$197.12M
Net income
-$179.18M
EPS, diluted
-$2.76
Free cash flow
–
Reported periodTrailing twelve months